Babson Diagnostics, an Austin, TX-based science-first healthcare technology company, received a strategic investment from Becton Dickinson and Company.
The amount of the deal was not disclosed. Becton, Dickinson and Company joined Siemens Healthineers, an existing strategic investor, and Emerald Development Managers LP, a Series B lead investor, to provide new financing to support Babson’s commercial launch.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO David Stein, Babson Diagnostics is a science-first healthcare technology company reimagining the diagnostic blood testing experience through clinical research.
In May, Babson launched BetterWay blood testing at local pharmacies in Austin, which is an innovation in diagnostic testing, using a small amount of blood, about the size of a pea, from a fingertip to diagnose and monitor a variety of chronic conditions, from hypertension to high cholesterol.
FinSMEs
09/10/2024